The Importance of Subgroup Analysis in Drug-Eluting Stent Trials

Saved in:
Bibliographic Details
Published in:JACC. Cardiovascular interventions 2016-01, Vol.9 (1), p.39-41
Main Author: Abbott, J. Dawn, MD
Format: Article
Language:English
Subjects:
Cardiovascular
chronic kidney disease
Coronary Artery Disease - drug therapy
Coronary Restenosis - drug therapy
drug-eluting stent(s)
Drug-Eluting Stents
Humans
Myocardial Infarction - drug therapy
Paclitaxel
Sirolimus - therapeutic use
Stents
Time Factors
Treatment Outcome
women
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3706-378cb2b473bfa8a1c6c353aee5704dcc9d5e3c7b6904f7b9f9166b1e1401467c3
cites cdi_FETCH-LOGICAL-c3706-378cb2b473bfa8a1c6c353aee5704dcc9d5e3c7b6904f7b9f9166b1e1401467c3
container_end_page 41
container_issue 1
container_start_page 39
container_title JACC. Cardiovascular interventions
container_volume 9
creator Abbott, J. Dawn, MD
description
doi_str_mv 10.1016/j.jcin.2015.11.006
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1760866624</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S193687981501701X</els_id><sourcerecordid>1760866624</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3706-378cb2b473bfa8a1c6c353aee5704dcc9d5e3c7b6904f7b9f9166b1e1401467c3</originalsourceid><addsrcrecordid>eNp9kc1L7DAUxYMofv8DLh5dumnNbdqkAZE3-A2CixnBXUjT2zF9nXZe0grz35sy6sKFq3sX5xw4v0PIGdAEKPCLJmmM7ZKUQp4AJJTyHXIIheCx4DTfDb9kPC6ELA7IkfdNEFAp0n1ykHLBU0nlIfm7eMPocbXu3aA7g1FfR_OxXLp-XEezTrcbb31ku-jGjcv4th0H2y2j-YDdEC2c1a0_IXt1OHj6eY_Jy93t4vohfnq-f7yePcWGCcpjJgpTpmUmWFnrQoPhhuVMI-aCZpUxssqRGVFySbNalLKWwHkJCBmFjAvDjsn5Nnft-v8j-kGtrDfYtrrDfvQKQueCc55mQZpupcb13jus1drZlXYbBVRN5FSjJnJqIqcAVAATTH8-88dyhdW35QtVEFxuBRhavlt0yhuLgVllHZpBVb39Pf_qh920trNGt_9wg77pRxdwhx7Kp4qq-bTdNB3kFASFV_YBYGuTGA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1760866624</pqid></control><display><type>article</type><title>The Importance of Subgroup Analysis in Drug-Eluting Stent Trials</title><source>BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS</source><creator>Abbott, J. Dawn, MD</creator><creatorcontrib>Abbott, J. Dawn, MD</creatorcontrib><identifier>ISSN: 1936-8798</identifier><identifier>ISSN: 1876-7605</identifier><identifier>EISSN: 1876-7605</identifier><identifier>DOI: 10.1016/j.jcin.2015.11.006</identifier><identifier>PMID: 26762909</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Cardiovascular ; chronic kidney disease ; Coronary Artery Disease - drug therapy ; Coronary Restenosis - drug therapy ; drug-eluting stent(s) ; Drug-Eluting Stents ; Humans ; Myocardial Infarction - drug therapy ; Paclitaxel ; Sirolimus - therapeutic use ; Stents ; Time Factors ; Treatment Outcome ; women</subject><ispartof>JACC. Cardiovascular interventions, 2016-01, Vol.9 (1), p.39-41</ispartof><rights>American College of Cardiology Foundation</rights><rights>2016 American College of Cardiology Foundation</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3706-378cb2b473bfa8a1c6c353aee5704dcc9d5e3c7b6904f7b9f9166b1e1401467c3</citedby><cites>FETCH-LOGICAL-c3706-378cb2b473bfa8a1c6c353aee5704dcc9d5e3c7b6904f7b9f9166b1e1401467c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26762909$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abbott, J. Dawn, MD</creatorcontrib><title>The Importance of Subgroup Analysis in Drug-Eluting Stent Trials</title><title>JACC. Cardiovascular interventions</title><addtitle>JACC Cardiovasc Interv</addtitle><subject>Cardiovascular</subject><subject>chronic kidney disease</subject><subject>Coronary Artery Disease - drug therapy</subject><subject>Coronary Restenosis - drug therapy</subject><subject>drug-eluting stent(s)</subject><subject>Drug-Eluting Stents</subject><subject>Humans</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Paclitaxel</subject><subject>Sirolimus - therapeutic use</subject><subject>Stents</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>women</subject><issn>1936-8798</issn><issn>1876-7605</issn><issn>1876-7605</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp9kc1L7DAUxYMofv8DLh5dumnNbdqkAZE3-A2CixnBXUjT2zF9nXZe0grz35sy6sKFq3sX5xw4v0PIGdAEKPCLJmmM7ZKUQp4AJJTyHXIIheCx4DTfDb9kPC6ELA7IkfdNEFAp0n1ykHLBU0nlIfm7eMPocbXu3aA7g1FfR_OxXLp-XEezTrcbb31ku-jGjcv4th0H2y2j-YDdEC2c1a0_IXt1OHj6eY_Jy93t4vohfnq-f7yePcWGCcpjJgpTpmUmWFnrQoPhhuVMI-aCZpUxssqRGVFySbNalLKWwHkJCBmFjAvDjsn5Nnft-v8j-kGtrDfYtrrDfvQKQueCc55mQZpupcb13jus1drZlXYbBVRN5FSjJnJqIqcAVAATTH8-88dyhdW35QtVEFxuBRhavlt0yhuLgVllHZpBVb39Pf_qh920trNGt_9wg77pRxdwhx7Kp4qq-bTdNB3kFASFV_YBYGuTGA</recordid><startdate>20160111</startdate><enddate>20160111</enddate><creator>Abbott, J. Dawn, MD</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160111</creationdate><title>The Importance of Subgroup Analysis in Drug-Eluting Stent Trials</title><author>Abbott, J. Dawn, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3706-378cb2b473bfa8a1c6c353aee5704dcc9d5e3c7b6904f7b9f9166b1e1401467c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Cardiovascular</topic><topic>chronic kidney disease</topic><topic>Coronary Artery Disease - drug therapy</topic><topic>Coronary Restenosis - drug therapy</topic><topic>drug-eluting stent(s)</topic><topic>Drug-Eluting Stents</topic><topic>Humans</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Paclitaxel</topic><topic>Sirolimus - therapeutic use</topic><topic>Stents</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abbott, J. Dawn, MD</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>JACC. Cardiovascular interventions</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abbott, J. Dawn, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Importance of Subgroup Analysis in Drug-Eluting Stent Trials</atitle><jtitle>JACC. Cardiovascular interventions</jtitle><addtitle>JACC Cardiovasc Interv</addtitle><date>2016-01-11</date><risdate>2016</risdate><volume>9</volume><issue>1</issue><spage>39</spage><epage>41</epage><pages>39-41</pages><issn>1936-8798</issn><issn>1876-7605</issn><eissn>1876-7605</eissn><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26762909</pmid><doi>10.1016/j.jcin.2015.11.006</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1936-8798
ispartof JACC. Cardiovascular interventions, 2016-01, Vol.9 (1), p.39-41
issn 1936-8798
1876-7605
1876-7605
language eng
recordid cdi_proquest_miscellaneous_1760866624
source BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS
subjects Cardiovascular
chronic kidney disease
Coronary Artery Disease - drug therapy
Coronary Restenosis - drug therapy
drug-eluting stent(s)
Drug-Eluting Stents
Humans
Myocardial Infarction - drug therapy
Paclitaxel
Sirolimus - therapeutic use
Stents
Time Factors
Treatment Outcome
women
title The Importance of Subgroup Analysis in Drug-Eluting Stent Trials
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T10%3A45%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Importance%20of%20Subgroup%20Analysis%20in%20Drug-Eluting%20Stent%20Trials&rft.jtitle=JACC.%20Cardiovascular%20interventions&rft.au=Abbott,%20J.%20Dawn,%20MD&rft.date=2016-01-11&rft.volume=9&rft.issue=1&rft.spage=39&rft.epage=41&rft.pages=39-41&rft.issn=1936-8798&rft.eissn=1876-7605&rft_id=info:doi/10.1016/j.jcin.2015.11.006&rft_dat=%3Cproquest_cross%3E1760866624%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3706-378cb2b473bfa8a1c6c353aee5704dcc9d5e3c7b6904f7b9f9166b1e1401467c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1760866624&rft_id=info:pmid/26762909&rfr_iscdi=true